Longevity is being reshaped by spending and outcomes, but the split is surprisingly uneven. Global health R&D took 8.0% of health spending in 2021, while total healthcare consumption is far broader, with the US at 6.3% of GDP in 2022 and low-income countries at just 3.6% of global GDP in healthcare in the same period. As the care burden grows with 1.5 billion people aged 65+ projected by 2050, these funding and survival metrics start to reveal where progress is accelerating and where it still lags.
Key Takeaways
- 8.0% global health spending share spent on health R&D in 2021
- $2.7 trillion global long-term care spending in 2019 (latest global estimate widely cited by OECD)
- 6.3% of GDP spent on healthcare in the United States in 2022
- 1.5 billion people aged 65+ worldwide in 2050 projected by UN
- 11.3% share of global population aged 65+ in 2019
- US life expectancy at birth was 77.5 years in 2022 (CDC)
- In-hospital mortality for heart failure was 4.3% in 2022 (AHA/NCDB)
- Cancer 5-year relative survival rate was 67% (US, 2015-2019, NCI SEER)
- Breast cancer 5-year relative survival was 91% (US, 2015-2019, NCI SEER)
- Australia life expectancy at birth was 84.3 years in 2022 (World Bank)
- UK life expectancy at birth was 81.3 years in 2022 (World Bank)
- In the US, 73% of adults have used health information online (Pew Research Center, 2019)
- US FDA approved 77 drug approvals in 2022 (CDER annual report)
- US FDA approved 55 new molecular entities/BLAs in 2021 (FDA CDER)
- Per-capita healthcare spending in Switzerland was $10,381 (current US$) in 2022 (World Bank)
Spending and longevity tech are rising fast, while heart disease, cancer, and dementia still drive major deaths.
Related reading
Market Size
18.0% global health spending share spent on health R&D in 2021[1]
Verified
2$2.7 trillion global long-term care spending in 2019 (latest global estimate widely cited by OECD)[2]
Verified
36.3% of GDP spent on healthcare in the United States in 2022[3]
Verified
415.3% of GDP spent on healthcare in Germany in 2022[4]
Directional
514.8% of GDP spent on healthcare in France in 2022[5]
Verified
63.6% of total global GDP spent on healthcare in low-income countries in 2022[6]
Verified
7$7,954 per capita current health expenditure in the United States in 2021[7]
Verified
8$4,324 per capita current health expenditure (PPP) in Germany in 2021[8]
Verified
9$3,944 per capita current health expenditure (PPP) in France in 2021[9]
Single source
10$3.0 trillion global spending on healthcare IT services in 2022[10]
Verified
11$90.0 billion global market size for remote patient monitoring in 2023 (forecast)[11]
Verified
12$27.9 billion global market size for senior care services in 2022 (forecast)[12]
Verified
13$13.6 billion global market size for assisted living services in 2022 (forecast)[13]
Verified
14$4.1 billion global market size for home healthcare services in 2022 (forecast)[14]
Verified
15$15.0 billion global market size for wearable devices in healthcare in 2023 (forecast)[15]
Verified
16$21.7 billion global market size for longevity market services in 2023 (market estimate)[16]
Verified
17$19.4 billion global market size for the geriatric care market in 2021 (forecast)[17]
Verified
18$54.5 billion global market size for anti-aging products in 2023[18]
Verified
19$2.7 billion global market size for telerehabilitation in 2023 (forecast)[19]
Verified
20$2.9 billion global market size for AI in healthcare in 2020; $99.6 billion forecast by 2030[20]
Verified
21$55.2 billion global market size for digital therapeutics in 2022; $251.7 billion forecast by 2032[21]
Single source
Market Size Interpretation
The market size data shows rapid expansion across health and longevity services, with global spending rising from $90.0 billion for remote patient monitoring in 2023 to $21.7 billion for longevity market services in 2023 and even larger long-term growth forecasts like AI in healthcare expanding from $2.9 billion in 2020 to $99.6 billion by 2030.
More related reading
Industry Trends
11.5 billion people aged 65+ worldwide in 2050 projected by UN[22]
Directional
211.3% share of global population aged 65+ in 2019[23]
Verified
3US life expectancy at birth was 77.5 years in 2022 (CDC)[24]
Verified
4Japan life expectancy at birth was 84.2 years in 2022 (World Bank)[25]
Single source
5Global healthy life expectancy at birth was 61.1 years in 2019[26]
Verified
6Cancer caused 10.0 million deaths in 2020 (WHO)[27]
Verified
77.4 million deaths from air pollution in 2019 (WHO)[28]
Verified
8Dementia affects an estimated 55 million people worldwide (WHO)[29]
Verified
926.9 million Americans aged 65+ had disabilities in 2019 (US ACS)[30]
Verified
10$12.5 billion global funding in longevity/age-tech startups in 2021 (PitchBook, age tech/health-tech)[31]
Verified
Industry Trends Interpretation
With the UN projecting 1.5 billion people aged 65+ worldwide by 2050 and $12.5 billion flowing into longevity and age tech startups in 2021, the industry is rapidly scaling to meet rising needs driven by longer lives and major health burdens like cancer at 10.0 million deaths in 2020.
Performance Metrics
1In-hospital mortality for heart failure was 4.3% in 2022 (AHA/NCDB)[32]
Single source
2Cancer 5-year relative survival rate was 67% (US, 2015-2019, NCI SEER)[33]
Single source
3Breast cancer 5-year relative survival was 91% (US, 2015-2019, NCI SEER)[34]
Verified
4In the US, 1-year survival for localized prostate cancer exceeded 99% (SEER)[35]
Verified
5Strokes mortality in the US was 133.5 deaths per 100,000 population in 2022 (CDC)[36]
Verified
6Ischemic heart disease death rate was 113.9 per 100,000 population in 2022 (CDC)[37]
Directional
7Blood pressure control (treated and at goal) among US adults was 52% in 2017-2018 (CDC/NCHS)[38]
Verified
8Average waiting time for elective treatment in England was 7.9 weeks in 2023-24 (NHS England)[39]
Single source
9UK delayed transfers of care averaged 22,000 patients in March 2024 (NHS England)[40]
Directional
10Median age at death in the US was 77.0 years in 2022 (NCHS)[41]
Verified
11Life expectancy gains: global life expectancy at birth increased from 66.8 years in 2000 to 73.0 years in 2019 (UN/World)[42]
Verified
12Global premature mortality from non-communicable diseases accounted for 37% of NCD deaths under age 70 (WHO GHO)[43]
Verified
Performance Metrics Interpretation
Across major performance metrics for health outcomes, survival and care quality show strong variation, with breast cancer 5-year relative survival at 91% and localized prostate cancer 1-year survival above 99% contrasting sharply with higher population-level burdens like ischemic heart disease at 113.9 deaths per 100,000 and strokes at 133.5 deaths per 100,000 in 2022.
More related reading
User Adoption
1Australia life expectancy at birth was 84.3 years in 2022 (World Bank)[44]
Verified
2UK life expectancy at birth was 81.3 years in 2022 (World Bank)[45]
Verified
3In the US, 73% of adults have used health information online (Pew Research Center, 2019)[46]
Verified
4In the US, 38% of adults track health or fitness data using devices/apps (Pew Research Center, 2023)[47]
Verified
5In the US, 49% of adults say they have a wearable device used for fitness/health (Pew Research Center, 2023)[48]
Directional
6In Germany, 41% of people used online medical information in 2022 (Eurobarometer)[49]
Verified
7In the EU, 46% of people used the internet to find medical information in 2022 (Eurobarometer)[50]
Verified
8In the UK, 14.9% of people used digital health tools in the last 12 months (NHS)[51]
Directional
9In the US, 60% of adults report taking dietary supplements in 2017-2018 (NIH NHANES)[52]
Single source
10$1.64 billion global market for direct-to-consumer longevity testing in 2023 (forecast)[53]
Verified
11BioTech funding for aging/longevity-focused startups reached $5.5B in 2021 (Dealroom)[54]
Verified
User Adoption Interpretation
User adoption is surging from information seeking to active self tracking, with 73% of US adults using health information online and 38% tracking fitness or health data with devices or apps, alongside strong momentum in wearable and testing markets like a $1.64 billion direct to consumer longevity testing forecast for 2023.
More related reading
Cost Analysis
1US FDA approved 77 drug approvals in 2022 (CDER annual report)[55]
Verified
2US FDA approved 55 new molecular entities/BLAs in 2021 (FDA CDER)[56]
Verified
3Per-capita healthcare spending in Switzerland was $10,381 (current US$) in 2022 (World Bank)[57]
Verified
4Per-capita healthcare spending in India was $2,041 (current US$ PPP) in 2022 (World Bank)[58]
Verified
5UK NHS cost of a hospital bed day averaged £485 in 2022-23 (NHS Reference Costs)[59]
Directional
Cost Analysis Interpretation
From a Cost Analysis perspective, the sharp disparity in per-capita healthcare spending from Switzerland at $10,381 in 2022 to India at $2,041 in PPP terms, alongside the UK NHS average bed day cost of £485, suggests that the same drug or treatment availability gains can translate into very different system-level costs depending on country spending levels.
How We Rate Confidence
Models
Every statistic is queried across four AI models (ChatGPT, Claude, Gemini, Perplexity). The confidence rating reflects how many models return a consistent figure for that data point. Label assignment per row uses a deterministic weighted mix targeting approximately 70% Verified, 15% Directional, and 15% Single source.
Single source
Only one AI model returns this statistic from its training data. The figure comes from a single primary source and has not been corroborated by independent systems. Use with caution; cross-reference before citing.
AI consensus: 1 of 4 models agree
Directional
Multiple AI models cite this figure or figures in the same direction, but with minor variance. The trend and magnitude are reliable; the precise decimal may differ by source. Suitable for directional analysis.
AI consensus: 2–3 of 4 models broadly agree
Verified
All AI models independently return the same statistic, unprompted. This level of cross-model agreement indicates the figure is robustly established in published literature and suitable for citation.
AI consensus: 4 of 4 models fully agree
Models
Cite This Report
This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.
APA
Megan Gallagher. (2026, February 13). Longevity Statistics. Gitnux. https://gitnux.org/longevity-statistics
MLA
Megan Gallagher. "Longevity Statistics." Gitnux, 13 Feb 2026, https://gitnux.org/longevity-statistics.
Chicago
Megan Gallagher. 2026. "Longevity Statistics." Gitnux. https://gitnux.org/longevity-statistics.
References
- 1apps.who.int/gho/data/node.main.1224
- 2oecd-ilibrary.org/social-issues-migration-health/health-at-a-glance-2019-long-term-care_5d7f0b7d-en
- 3data.worldbank.org/indicator/SH.XPD.CHEX.GD.ZS?locations=US
- 4data.worldbank.org/indicator/SH.XPD.CHEX.GD.ZS?locations=DE
- 5data.worldbank.org/indicator/SH.XPD.CHEX.GD.ZS?locations=FR
- 6data.worldbank.org/indicator/SH.XPD.CHEX.GD.ZS?locations=ZG
- 7data.worldbank.org/indicator/SH.XPD.CHEX.PP.CD?locations=US
- 8data.worldbank.org/indicator/SH.XPD.CHEX.PP.CD?locations=DE
- 9data.worldbank.org/indicator/SH.XPD.CHEX.PP.CD?locations=FR
- 25data.worldbank.org/indicator/SP.DYN.LE00.IN?locations=JP
- 44data.worldbank.org/indicator/SP.DYN.LE00.IN?locations=AU
- 45data.worldbank.org/indicator/SP.DYN.LE00.IN?locations=GB
- 57data.worldbank.org/indicator/SH.XPD.CHEX.PP.CD?locations=CH
- 58data.worldbank.org/indicator/SH.XPD.CHEX.PP.CD?locations=IN
- 10gartner.com/en/newsroom/press-releases/2023-02-23-gartner-forecast-worldwide-it-spending-grow-to-5-1-trillion-in-2023
- 11grandviewresearch.com/industry-analysis/remote-patient-monitoring-market
- 20grandviewresearch.com/industry-analysis/artificial-intelligence-ai-in-healthcare-market
- 21grandviewresearch.com/industry-analysis/digital-therapeutics-market
- 12businesswire.com/news/home/20230316005253/en/Senior-Care-Services-Market-to-Reach-83-9-Billion-by-2030-at-7-1-CAGR-Fortune-Business-Insights
- 13alliedmarketresearch.com/assisted-living-market-A11464
- 14precedenceresearch.com/home-healthcare-services-market
- 15idc.com/getdoc.jsp?containerId=US51252523
- 16fortunebusinessinsights.com/longevity-market-106816
- 17marketsandmarkets.com/Market-Reports/geriatric-care-market-131471056.html
- 18marketsandmarkets.com/Market-Reports/anti-aging-products-market-1104.html
- 19researchandmarkets.com/reports/5949175/telerehabilitation-market-global-opportunities-and
- 22un.org/development/desa/pd/content/world-population-prospects-2022
- 23un.org/development/desa/pd/content/world-population-ageing-2019
- 24cdc.gov/nchs/fastats/life-expectancy.htm
- 30cdc.gov/nchs/products/databriefs/db419.htm
- 36cdc.gov/nchs/fastats/stroke.htm
- 37cdc.gov/nchs/fastats/heart-disease.htm
- 38cdc.gov/nchs/products/databriefs/db375.htm
- 41cdc.gov/nchs/products/databriefs/db480.htm
- 26ghoapi.azureedge.net/api/Indicator?$filter=IndicatorCode%20eq%20HALE
- 27who.int/news-room/fact-sheets/detail/cancer
- 28who.int/news-room/fact-sheets/detail/ambient-(outdoor)-air-quality-and-health
- 29who.int/news-room/fact-sheets/detail/dementia
- 43who.int/data/gho/data/themes/noncommunicable-diseases
- 31pitchbook.com/news/reports/age-tech-report-2022
- 32heart.org/-/media/files/professional/quality-improvement/heart-attack-and-stroke-care/timelines-and-reporting/2022-statistical-report.pdf
- 33seer.cancer.gov/statfacts/html/common.html
- 34seer.cancer.gov/statfacts/html/breast.html
- 35seer.cancer.gov/statfacts/html/prost.html
- 39england.nhs.uk/statistics/statistical-work-areas/referral-to-treatment-waiting-times/
- 40england.nhs.uk/statistics/statistical-work-areas/delayed-transfers-of-care/
- 42ourworldindata.org/life-expectancy
- 46pewresearch.org/internet/2019/04/22/health-online/
- 47pewresearch.org/internet/2023/08/15/people-are-using-ai-tools-but-their-impact-is-not-yet-clear/
- 48pewresearch.org/science/2022/05/10/usb-and-mobile-phone-access/
- 49europa.eu/eurobarometer/surveys/detail/2240
- 50europa.eu/eurobarometer/surveys/detail/2722
- 51nhs.uk/nhs-services/online-services/
- 52ods.od.nih.gov/factsheets/Dietary_Supplements-Consumer_Usage_and_Impact/
- 53globenewswire.com/news-release/2024/02/22/2830530/0/en/Direct-to-Consumer-Longevity-Testing-Market-to-Reach-4-8-Billion-by-2030-at-CAGR-20-5-Forecast-by-Report-Store.html
- 54dealroom.co/report/longevity-2022
- 55fda.gov/media/165915/download
- 56fda.gov/media/150409/download
- 59improvement.nhs.uk/documents/CRS%20Reference%20Costs%202022-23%20template.pdf